about
Genetic and epigenetic alterations in pancreatic carcinogenesisPeroxisome proliferator activated receptors at the crossroad of obesity, diabetes, and pancreatic cancerSelection criteria in resectable pancreatic cancer: a biological and morphological approachPathobiological implications of MUC16 expression in pancreatic cancer.Pathological features and diagnosis of intraductal papillary mucinous neoplasm of the pancreas.Risk factors for pancreatic cancer: underlying mechanisms and potential targets.Precursor lesions for sporadic pancreatic cancer: PanIN, IPMN, and MCN.Diagnosis of pancreatic neoplasms using a novel method of DNA methylation analysis of mucin expression in pancreatic juice.A concise review on the current understanding of pancreatic cancer stem cellsThe National Cancer Institute's PREVENT Cancer Preclinical Drug Development Program: overview, current projects, animal models, agent development strategies, and molecular targetsCancer immunoprevention.Role of MUC20 overexpression as a predictor of recurrence and poor outcome in colorectal cancerGenomic sequencing of key genes in mouse pancreatic cancer cells.Isoprenylcysteine carboxylmethyltransferase deficiency exacerbates KRAS-driven pancreatic neoplasia via Notch suppression.Significance of mucin expression in pancreatobiliary neoplasms.Mucins in human neoplasms: clinical pathology, gene expression and diagnostic application.Mucins in pancreatic cancer and its microenvironment.SMAD4 and its role in pancreatic cancer.MUC4 mucin- a therapeutic target for pancreatic ductal adenocarcinoma.Diagnostic value of selected markers and apoptotic pathways for pancreatic cancer.Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines.Aberrant methylation of MUC1 and MUC4 promoters are potential prognostic biomarkers for pancreatic ductal adenocarcinomas.Polymorphisms in microRNA binding sites of mucin genes as predictors of clinical outcome in colorectal cancer patients.Reappraisal of the Immunophenotype of Pancreatic Intraductal Papillary Mucinous Neoplasms (IPMNs)-Gastric Pyloric and Small Intestinal Immunophenotype Expression in Gastric and Intestinal Type IPMNs-.hsa-miR-96 and hsa-miR-217 Expression Down-Regulates with Increasing Dysplasia in Pancreatic Intraepithelial Neoplasias and Intraductal Papillary Mucinous Neoplasms.Preventing cancer by targeting abnormally expressed self-antigens: MUC1 vaccines for prevention of epithelial adenocarcinomas.Well-differentiated pancreatic ductal adenocarcinomas measuring ≤ 1 cm exhibit early features of tumor progression: a report of five lesions and a comparative study with advanced lesions.Quantitative proteomic analysis of pancreatic cyst fluid proteins associated with malignancy in intraductal papillary mucinous neoplasms.
P2860
Q24598655-4A68B9B5-7F3F-4DE4-9872-D8F5520F21F4Q26764921-5DDF70A4-B28C-4268-97B6-A56949283D52Q26859742-A2F3AAFB-73C4-4E19-B947-F44998ED7EEDQ34069612-7040B459-91D9-4487-A701-524248259556Q34179171-F61305C6-5F5F-4B87-B9D6-7553B0A77907Q34400723-BCE2F98C-0C86-47EB-99F0-1B419AAF1585Q34661643-39D64033-E252-4F8D-BA88-A4D227C7F9C4Q35143147-2CB6C31F-6BB3-43C7-A0CE-1256399C8BD1Q35801362-0BF60655-A17E-47A4-857B-0DB63561BF69Q36682108-661E183A-6BD3-477F-900B-2AE7C0A55F7EQ36723234-26A5E47C-AF97-41CC-919B-7E77E1066CACQ36985602-B585DD11-9F89-4B7F-82FA-1741DF46C907Q37237804-19223BB6-8E47-42FF-8CBC-619A243A2782Q37259201-FA3F101D-6B42-4F6A-9686-394AD4B7EF9FQ37604931-6B5D30A6-5919-4BD3-9CC6-D3AE0C2BBC3CQ37962623-15336781-F643-4826-86C5-2DCB76E25770Q38121746-004BB758-AAE6-4F30-B3CC-579DB3BE6FBCQ38281261-074E4007-7AE1-4DF6-8E36-9DE5F992D62DQ38688917-5D93F87C-C567-4CEB-AABD-6A8BC3D8575CQ38815842-7304EDB4-5D25-4008-9047-245ABB7E60C0Q39189908-56649C12-C051-4B02-8242-33A7344D180AQ39544250-5670A456-B456-43DA-A9A2-7138F23B5164Q40497823-F01A22CE-8ED8-4464-AADF-9CF60078338DQ41819714-F2191B8E-466B-4705-9EFC-F0570636B557Q42250458-FFCA2E1A-DD5E-4997-9A2F-68406F021DBAQ44241932-2AE196DF-C43F-41FD-94B9-5B02A1799477Q54501671-4CAE329C-133E-42B5-B349-24B1365DCDFDQ55387536-52659F99-FE84-484B-ABB7-5AB3B6D060D2
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Precursor lesions of pancreatic cancer.
@ast
Precursor lesions of pancreatic cancer.
@en
type
label
Precursor lesions of pancreatic cancer.
@ast
Precursor lesions of pancreatic cancer.
@en
prefLabel
Precursor lesions of pancreatic cancer.
@ast
Precursor lesions of pancreatic cancer.
@en
P2093
P2860
P356
P1433
P1476
Precursor lesions of pancreatic cancer.
@en
P2093
Masamichi Goto
Michiyo Higashi
Norishige Yamada
Suguru Yonezawa
P2860
P304
P356
10.5009/GNL.2008.2.3.137
P577
2008-12-31T00:00:00Z